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Objectives: The frequency of hepatitis G virus exposure in blood donors varies between 2.5% in
Japan to 24.2% in Poland. Therefore there is a geographic difference in distribution of hepatitis G
virus (HGV) in the world. We aimed to determine the frequency of HGV exposure in Iranian blood
donors.
Methods: Blood samples from 478 Iranian volunteer blood donors were tested. Positive anti-E2
samples were tested for HGV RNA by reverse transcriptase polymerase chain reaction (RT PCR)
using primers derived from the NS5A region of the viral genome.
Results: Of the 478 donors enrolled in our study, five (1%) were positive for anti-E2. Only one
donor out of a total of three HBsAg-positive donors was co-infected with HGV, but we did not find
HGV and HCV co-infection in our subjects. HGV RNA was not observed in the five anti-E2-positive
subjects. We did not find HGV viremia and antibody at the same time.
Conclusion: A low frequency of HGV exposure in blood donors was found in this study. We did not
observe co-infection of HGV with HCV in our subjects, supporting the theory that although the
parenteral route is the most effective means of transmission, other routes such as sexual contact
and intra-familial contact may also play a role in HGV transmission.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +98 2188361922;
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Hepatitis G virus (HGV) is a single-stranded RNA virus that
represents a newly discovered virus belonging to the flavi-
virus family. Epidemiological data indicate that the virus isPublished by Elsevier Ltd. All rights reserved.
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cally from infected mothers to children.1 The virus has
worldwide distribution with varying prevalence in blood
donor populations from different parts of the world, ranging
from 1% in the UK2 to 18.2% in South Africa.3 Most HGV
infections appear to be asymptomatic. The clinical signifi-
cance of this agent is still uncertain; several studies
have failed to demonstrate serious liver disease in patients
with HGV viremia,2 although the possibility of it having a
role in fulminant hepatitis4,5 and aplastic anemia has been
debated.6
In the absence of any reliable serological assay for the
diagnosis of infection, HGV RNA detection by reverse tran-
scriptase polymerase chain reaction (RT-PCR) remains the
only available method indicating an ongoing HGV infection.7
An ELISA has been developed for the detection of anti-
bodies against the HGV envelope protein E2 (anti-E2).8
The presence of serum anti-E2 is usually associated with
the clearance of serum HGV RNA in patients infected
with the virus.7,9,10 E2 antibodies are considered useful mar-
kers for diagnosing recovery from HGV infections. Anti-E2 can
persist for years after clearance of the virus and simultaneous
presence of viremia and anti-E2 is very rarely found.9 Anti-E2
has been found in >5% of blood donors and in up to 68% of
persons in high-risk groups such as intravenous drug users.9 In
European donors, the prevalence of anti-E2 indicating
resolved infection ranges from 3% to 14%.11
HGV has common parenteral risk factors to other hepatitis
viruses. The co-infection rate of HGVand HCV in blood donors
has been found to be 3.4—24.4% depending on risk factors,
andwith HBV has been found to be 32%.12 Co-infection of HGV
with other hepatitis viruses may contribute to changes in the
evolution of liver disease. But several studies have suggested
that HGV co-infection does not seem to affect the course of
viral hepatitis.9,10,13,14
To date no country has made a decision to screen HGV in
blood donors; however, further studies are necessary to
establish the influence of HGV infection on human health
and also in the context of other viral infections.
The aim of this study was to determine the frequency of
HGV exposure (past infection) in Iranian blood donors as well
as co-infection with hepatitis B and hepatitis C virus, and also
the co-existence of HGV RNA and anti-HGV.
Patients and methods
This study was performed from April to June 2005 on volun-
teer blood donors in the city of Tabriz, Iran. Four hundred and
seventy-eight blood samples (465 men and 13 women) were
collected from donations of unpaid volunteer blood donors;
plasma was stored at 80 8C and donors interviewed to
determine place of residence (455 from urban and 23 from
rural areas).
All were tested for liver enzymes including alanine ami-
notransferase (ALT) and aspartate aminotransferase (AST) by
routine laboratory techniques. All samples were tested for
hepatitis B surface antigen (HBsAg), hepatitis C virus anti-
body (HCV-Ab), and anti-HGV envelope protein E2 (anti-E2)
by enzyme-linked immunosorbent assay (ELISA). The com-
mercial HBsAg enzyme immunoassays kits were the OQPW13
Enzygnost1 HBsAg 5.0 (Dade Behring, Marburg, Germany),anti-HCV determination kits were from Avicenna Medical
Center (Moscow, Russia), and anti E2 kits were mPLATE
Anti-Hgenv (Boehringer GmbH, Mannheim, Germany). All
assay protocols, cut-offs, and result interpretations were
carried out according to the manufacturers’ instructions.
Recombinant immunoblot assay (RIBA Innogenetics, Ghent,
Belgium) was employed to confirm anti-HCV reactivity.
RT-PCR
Anti-E2-positive samples were tested for HGV RNA by RT-PCR
using primers derived from the NS5A region of the viral
genome. RNA was purified using 200 ml of plasma from each
sample using NucleoSpin1 RNA virus (Machery-Nagel GmbH,
Germany) following the manufacturer’s instructions. RNA
was converted to cDNA using the Surescript One-Step RT-
PCR using random hexamer primer at 37 8C for one hour.
Subsequently, cDNA was amplified, in the same tube, using a
denaturation step at 94 8C for 2 min, followed by 30 cycles of
denaturation at 94 8C for 30 s, annealing for 30 s at 55 8C, and
extension at 72 8C for 30 s. RT-PCR products were further
amplified using nested PCR (94 8C for 2 min, followed by 40
cycles of 94 8C for 45 s, 55 8C for 45 s, and 72 8C for 45 s) using
Hot Start Taq polymerase (Roche, Mannheim, Germany)). The
primers used in the RT-PCR/nested PCR were as follows:
G58 (outer; forward), 50-CAGGGTTGGTAGGTCGTAAATCC-
30
G75 (outer; reverse), 50-CCTATTGGTCAAGAGAGACAT-30
G134 (inner; forward), 50-GGTCAYCYTGGTAGCCACTA-
TAGG- 30
G131 (inner; reverse), 50-AAGAGAGACATTGWAGGGC-
GACGT-30
The inner primers should amplify a 208-bp region in the
50-UTR of HGV (bases 152 through 359).15,16 An HGV RNA-
positive sample was obtained from Dr Keivan’s laboratory
(Tehran, Iran) and was used as a positive control. PCR pro-
ducts were electrophoresed on a 1.5% agarose gel containing
ethidium bromide and a visualized gel documentation system
(Figure 1).
Statistical methods
The laboratory findings and personal data among the groups
studied were also compared using Chi-square and t2 tests
using SPSS 11.5 package program. Quantitative variables are
expressed as mean  standard deviation. A p-value of less
than 0.05 was considered statistically significant throughout
our data analyses.
Results
From the 478 blood donors enrolled in our study, five (1%)
were repeatedly positive for anti-E2. The mean age of blood
donors with positive anti-E2 was 33.6  7.3 years and in the
negative anti-E2 group was 33.6  9.9 years (not significant).
The mean AST levels in the positive and negative anti-E2
groups were 18.2  5.3 IU/l versus 20.9  8.2 IU/l and for
ALT, 21  5.1 IU/l versus 24.5  12.9 IU/l, respectively.
There was no significant difference between ALT and AST
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Figure 1 Agarose gel (1.5%) electrophoresis of PCR products.
From right: lane 1, DNA ladder; lane 2, negative control; lane 3,
positive control; lanes 4—8, anti-HGV-positive samples.levels in positive and negative anti-E2 groups. Anti-E2-posi-
tive subjects did not show elevation in liver enzymes includ-
ing AST and ALT levels.
We found nine anti-HCV-positive and three HBsAg-positive
blood donors. From the five anti-E2-positive samples, only
one was also positive for HBsAg and all were anti-HCV-nega-
tive. There was an association between anti-E2 positivity and
the presence of HBV marker ( p < 0.031). Only one donor out
of the total of three HBsAg-positive donors was co-infected
with HGV, but we did not find co-infection with HCV.
There was no significant difference between the anti-E2-
positive and negative samples with regard to age. We did not
observe any antibody-positive case in the female donors. All
five of the anti-E2-positive donors were from urban areas and
there was no positive sample from rural areas (not signifi-
cant).
HGV RNA was not found in anti-E2-positive cases. We did
not find HGV viremia and antibody at the same time.
Discussion
Evidence that HGV is a blood-borne agent warrants studies to
determine the prevalence of infection in blood donors in
various countries. The first aim of this study was to estimate
the rate of exposure to HGV in healthy blood donors as well as
those positive for HBV or HCV in Iran. We have shown a low
frequency of anti-E2 (1%) in blood donors accepted at the
Tabriz blood transfusion center. In European countries, anti-
E2 seropositivity in blood donors has been found to range
from 10.9% to 24.2%.17—20 In South Africa (20.3%)17 and Brazil
(19.5%),17 even higher anti-E2 prevalence rates have been
recorded. In Asian countries,17,21 anti-E2 positivity has been
found to be significantly lower (2.5—6.3%), although in blood
donors in Taiwan, a higher prevalence (10.2%) has been
reported.22
In other countries, anti-E2 has been found in 7.3% of
Canadian,23 10.5% of Norwegian,24 and 11.3% of Russian blood
donors.25 An even higher prevalence of exposure to HGV (52—
73%) has been found in several groups at risk of parenteralexposure to infectious agents, i.e., intravenous drug users,
those with a transfusion history, hemophiliacs, hemodialysis
patients, and hepatitis C virus (HCV)-positive patients.19 Most
anti-E2-positive patients were found to be HGV RNA-negative
and vice versa, indicating an inverse correlation of these two
viral markers.19
The prevalence of HGV RNA in blood donors has been
found to range from 1% to 18.2%.2,3,26—31 However, Kalkan
et al. reported no positivity for HGV RNA in Turkish blood
donors.32 Among individuals with parenteral risk factors, the
prevalence has been found to bemuch higher, reaching 18% in
hemophiliacs and 16—33% in intravenous drug users.33
The above studies have shown the wide variations in
different geographic areas. These conflicting results on
HGV prevalence in blood donors may be related to various
factors: the size of the study group, the methods used to
describe the HGV, and the demographic and clinical features
of the population. Also, differences in host susceptibility or
virulence of different strains of HGV may explain the differ-
ences.
HGV and HCV infections have frequently been found to be
associated and have common parenteral risk factors. The co-
infection rate of HGV with HCV in blood donors has been
found to be 3.4—24.4% depending on risk factors, and with
HBV 32%.12 In our study, from the three donors positive for
HBsAg, only one was also positive for anti-E2, but we did not
find HGV and HCV co-infection in our subjects. This is con-
sistent with the report of Praharaj et al.12 about co-infection
of HBV with HGV (29.4%) in blood donors, but contrasts with
the results of Tan et al. regarding co-infection of HGV with
HCV (33.3%).9 Panda et al. also failed to detect any co-
infection of HGV with hepatitis B or C.34
Some studies have shown a higher HGV co-infection with
HBV and HCV (50%) in blood donors.28 Al-Knawy from Saudi
Arabia reported that in patients with HCV infection, the co-
infection rate of HGV was 31%,35 higher than that observed in
Japan,36 Italy,31 and Southern China.29 These findings are in
agreement with other collected data on HCV-infected
patients13,33 and they may reflect a common route of trans-
mission and risk factors of the two agents. Our data regarding
HGV and HCV co-infection were not similar to other authors;
one possible explanation is the low prevalence of HCV and
HGV infection in our subjects and also HGV is capable of
independent transmission, indicating that additional routes
of viral transmission besides parenteral exposure might exist,
possibly sexual, vertical, or even by close contact, as
observed in HBV infection. There is a need to systematically
investigate the possible risk factors for HGV transmission.
Little information is available to date about the possible
influence of dual infection on the course of liver disease.
Some authors have discovered that co-infection with HGV has
a significant influence on histological findings of HCV hepa-
titis and that this co-infection could be important for the
enhancement of liver damage.21,22,37,38 Other studies have
shown that in individuals with HGVand HCV co-infection, the
HGV infection has no influence on HCV replication or HCV RNA
levels, and also it has no influence on the course of liver
damage.9,14,39—42
Some authors have found a very high prevalence of HGV
infection in chronic hepatitis B patients (CHB).43,44 Never-
theless, no evidence has been found that HGV co-infection
has any impact on the severity of chronic HBV infection or
60 A. Ramezani et al.changes the course of basic liver disease.43—45 However, the
significance of HGV infection with other viral hepatitis is still
not clear and needs further investigation.
The pathogenicity of HGV seems to be negligible.14 Our
findings agree with previous studies reporting that biochem-
ical evidence of liver inflammation is uncommon in patients
with HGV infection.14,31,41 None of our HGV-positive subjects
had elevated liver enzymes including ASTand ALT levels, and
we did not expect to observe this because all of our subjects
had cleared their infection and did not have viremia.
Most patients infected by HGV show only aminor elevation
in aminotransferase levels that lasts until the clearance of
HGV RNA.14,31 However the clinical implications of HGV
infection have not been clearly determined since the vast
majority of infected individuals do not show liver injury.
Roth etal. showeda significantly greaterprevalenceofHGV
in urban volunteer blood donors than in rural donors.30 The
high prevalence of HGV infection in urban donors suggested
specific transmission risks for this group. With respect to
parenteral transmission routes of HGV, it is conceivable that
urban donors are more likely to have had intravenous injec-
tions and to have subjected themselves more frequently to
medical (dental procedures, injections, etc.) and non-medical
(piercing, etc.) procedures. We did not observe anti-E2 posi-
tivity in the blood donors from rural areas in Tabriz. However
there were only 23 rural donors (low number) in our study,
therefore it cannot be concluded that there was an additional
transmission risk for HGV in the urban population of our study.
With regard to the scarcity of information on the pre-
valence of anti-envelope antibodies coinciding with HGV
viremia in Iran, we have used RT-PCR to detect the presence
of hepatitis G viremia in anti-E2-positive blood donors. We
did not find HGV RNA in our samples and all of our subjects
had cleared their infection probably by anti-E2 seroconver-
sion. In a previous study, 4% of drug users and 18% of patients
with transfusion-associated hepatitis were found to have
both anti-E2 and HGV RNA.8 These results are in concordance
with the studies published by Tan et al. (in HCV-positive
donors) who found that HGV RNA and anti-E2 were mutually
exclusive except in 1.5% of donors.9
Kondili et al. showed the presence of both markers in one
thalassemic patient in Italy.46 The temporal overlap between
anti-E2 seroconversion and loss of detectable HGV RNA may
last more than 6 months.46 Anti-E2 has been reported as a
marker of recovery from HGV infection, based on observa-
tions that HGV RNA and anti-E2 are generally mutually
exclusive and that clearance of HGV RNA generally coincides
with the appearance of anti-E2 antibody.7,9,10 Some studies
have shown that only 5% of individuals with any HGV marker
are positive for both HGV RNA and anti-E2.10 More studies are
necessary to establish whether the coexistence of HGV RNA
and anti-E2 heralds recovery from infection or whether it
signals infection with different strains of HGV.
HGV infection seems to occur in all ethnicities all over the
world. We observed a low frequency of anti-E2 in Iranian
blood donors (1%), and it seems that supervision and screen-
ing of blood donors will not be necessary. A more accurate
estimation of the prevalence of HGV infection can be
achieved with the determination of both HGV RNA and
anti-E2. Since only serological tests were performed (and
no PCR) in our study, the prevalence rate of HGV has been
underestimated and further clinical and epidemiologicalstudies on the prevalence rate of HGV RNA in blood donors
and recipients should be considered.
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